Co-Diagnostics (CODX) Q3 2025 Earnings Transcript [Yahoo! Finance]
Co-Diagnostics, Inc. (CODX)
US:NASDAQ Investor Relations:
ir.codiagnostics.com/investor-relations
Company Research
Source: Yahoo! Finance
Chief Executive Officer — Dwight H. Egan Chief Financial Officer — Brian L. Brown Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Dwight H. Egan, Chief Executive Officer, and Brian L. Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results from the third quarter ended 09/30/2025. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open the call to analysts Q and A. Before we begin, we would like to inform listeners that certain statements made by Co-Diagnostics during this call which are not historical facts, are forward-looking statements. In addition to diagnostic test developments and timing for commencement of clinical evaluations, this includes statements concerning the company's KodiX PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale. Actu
Show less
Read more
Impact Snapshot
Event Time:
CODX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CODX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CODX alerts
High impacting Co-Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
CODX
News
- Co-Diagnostics (NASDAQ:CODX) was upgraded by analysts at Maxim Group to a "hold" rating.MarketBeat
- Co-Diagnostics (NASDAQ:CODX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.MarketBeat
- Co-Diagnostics (NASDAQ:CODX) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung HealthPR Newswire
- Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDAPR Newswire
CODX
Earnings
- 11/13/25 - Beat
CODX
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- CODX's page on the SEC website